Coya Therapeutics (NASDAQ:COYA) Issues Quarterly Earnings Results

Coya Therapeutics (NASDAQ:COYA) released its quarterly earnings data on Tuesday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.11), FiscalAI reports. The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.11 million. Coya Therapeutics had a negative net margin of 643.44% and a negative return on equity of 66.91%.

Coya Therapeutics Trading Up 5.0%

Shares of NASDAQ:COYA traded up $0.16 during trading on Thursday, reaching $3.37. The stock had a trading volume of 53,146 shares, compared to its average volume of 178,547. The firm’s 50-day simple moving average is $4.34 and its 200 day simple moving average is $4.59. Coya Therapeutics has a one year low of $2.72 and a one year high of $6.62. The company has a market capitalization of $79.05 million, a P/E ratio of -2.41 and a beta of 0.70.

Analysts Set New Price Targets

COYA has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Thursday, October 15th. Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday, August 12th. Roth Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Coya Therapeutics in a research note on Monday, August 24th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Thursday. Finally, BTIG Research reaffirmed a “buy” rating and set a $16.00 target price on shares of Coya Therapeutics in a research report on Tuesday, September 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.